Two new studies by researchers at Makerere University School of Public Health (MakSPH) reveal a troubling pattern at the centre of Uganda’s escalating antimicrobial resistance (AMR) crisis, a public health challenge where disease-causing bacteria and other germs stop responding to known medicines meant to kill them, making common infections harder or more expensive to treat.

The studies, conducted in Wakiso and neighbouring districts and recently published in leading scientific journals, examined key drivers of AMR from distinct yet connected perspectives. Together, they expose a health system under strain; shaped by poor-quality medicines circulating in communities, high and often inappropriate antibiotic use in healthcare facilities, and limited public awareness of safe medicine use, conditions now reinforcing one another and accelerating drug resistance.

According to the Ministry of Health, AMR in Uganda has reached concerning levels. By March 2025, resistant infections were estimated to kill 37,800 people annually, with over 7,000 deaths directly caused by AMR and more than 30,000 linked to infections no longer responding to available treatment. This surge is driven by unrestricted access to antibiotics, weak drug-regulatory enforcement, and widespread misuse of antimicrobials in humans and animals.

The Ministry acknowledges that many patients are treated without diagnostic testing, while low public awareness and weak stewardship across human and veterinary health services continue to fuel microbial resistance. As a result, bacteria that once responded to routine antibiotics now show resistance rates of up to 80 per cent in some cases, undermining treatment outcomes, food safety, and household incomes. It is this challenge that informed the two MakSPH studies.

Two Studies, One Warning

Evidence from both studies points to the need for coordinated action to strengthen medicine quality, improve prescribing practices, and build community awareness to preserve the effectiveness of essential treatments. In the first paper, published on October 6, 2025, in the Journal of Pharmaceutical Policy and Practice, researchers led by Associate Professor David Musoke examined how consumers encounter and respond to substandard and falsified medicines for both human and animal use.

Conducted in 2024, the study surveyed 432 community members in Wakiso District, where the Nottingham Trent University – Makerere University (NTU–Mak) Partnership, initiated by NTU’s Prof. Linda Gibson and MakSPH’s Assoc. Prof. Musoke, has implemented community-based health systems programmes for 15 years now. Using a structured household questionnaire, the team assessed knowledge, attitudes, and everyday practices related to medicine use.

The second study, published on November 21 in the Dovepress Journal of Infection and Drug Resistance, was led by Dr. Bush Herbert Aguma, a pharmacist, health-systems researcher, and Lecturer in the Department of Pharmacy at Makerere University. Working with Assoc. Prof. Musoke and colleagues, the team applied the standardised Global Point Prevalence Survey (GPPS) to examine antibiotic prescribing across three hospitals and five lower-level health centres in Wakiso, Nakaseke, and Butambala. The survey assessed patient demographics, antimicrobial therapy details, and adherence to treatment guidelines to identify gaps requiring improvement.

The surveys were conducted at Entebbe Regional Referral Hospital, Gombe General Hospital, Nakaseke General Hospital, and five lower-level facilities in Wakiso, all part of the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) project at MakSPH implemented through the NTU–Mak Partnership. Alongside the surveys, the partnership has strengthened antimicrobial stewardship in these eight facilities through routine staff training, mentorship, community engagement, and capacity-building in infection prevention and control, microbiology, and detection of substandard and falsified medicines.

“The work was to empower the facility through its Medicines and Therapeutics Committee, which has a sub-committee on antimicrobial stewardship. That committee oversees the process, ensures future surveys are conducted, and can initiate targeted assessments when problems with specific prescriptions arise,” Dr. Herbert Bush Aguma, lead author of the second study, explained.

He added that the programme in the selected facilities for the study went beyond just measuring antimicrobial use, to supporting the facilities develop stewardship plans, strengthening laboratory capacity, and training health workers across human, animal and environmental sectors under a One Health approach. As a result, he stated, facilities can now independently conduct point prevalence surveys, identify prescribing gaps such as inappropriate ceftriaxone use, and advocate for improved diagnostics, while hospitals, Village Health Teams (VHTs), veterinary and environmental officers increasingly address AMR drivers within their settings, leading to significant and lasting impact.

Over the last 15 years, the NTU–Mak Partnership, as part of this work, has trained more than 600 health workers across the human, animal, and environmental sectors in Wakiso, Nakaseke, and Butambala, and equipped over 1,300 community health workers (VHTs) in Wakiso with practical AMR knowledge. University-led programmes, international student competitions, and a 900-member online Community of Practice have further extended its reach. Together, these initiatives demonstrate how sustained community engagement can translate national AMR priorities into real-world impact, offering a model for locally anchored AMR interventions while also supporting the generation of new evidence to strengthen health systems, including the current two studies.

What Communities Know, and Don’t Know, About Fake Medicines

In the first study, Assoc. Prof. Musoke and colleagues found that while 83 per cent of respondents had heard of substandard and falsified medicines, only 31 per cent could correctly define the terms, and just seven per cent could accurately identify a falsified product. According to the World Health Organisation (WHO), a global health watchdog, substandard and falsified medicines fail to meet quality standards or deliberately mimic genuine products, often containing the wrong, too little, or no active ingredients. Such medicines put patients at risk of treatment failure, toxicity, and death and accelerate antimicrobial resistance by exposing bacteria to ineffective drug levels.

In Wakiso, the most populous district in Uganda with over 3.3 million people, although over 95 per cent of respondents recognised substandard and falsified medicines as dangerous, many reported having purchased drugs they suspected to be fake: 14 per cent for human and 24 per cent for animal use. To check authenticity, residents relied on advice from health workers or veterinary officers and on buying from trusted outlets. Yet reporting remained extremely low, as only one in four informed a health worker when they suspected a problem, and still, just four per cent had ever reported a case to the National Drug Authority (NDA), mandated to regulate drugs in Uganda.

These patterns reveal a community that recognises the threat of poor-quality medicines but lacks the agency to act. As the study notes, “community members from a range of backgrounds had limited knowledge and poor practices despite commendable attitudes on substandard and falsified medicines… Many respondents reported never having purchased and used substandard and falsified medicines knowingly or unknowingly, although a good number suspected that a medicine they previously purchased had been substandard or falsified.”

In the second study on antibiotic prescribing, the researchers found high rates of antibiotic use across all eight public facilities. In the three hospitals, 87.2 per cent of inpatients were receiving at least one antibiotic, with ceftriaxone alone, the most commonly prescribed antibiotic in other studies, accounting for nearly one-third of all prescriptions. Most antibiotics were administered prophylactically, especially for obstetric and gynaecological surgeries, which made up 30.7 per cent of all hospital antibiotic use. In lower-level facilities, 60.7 per cent of outpatients received antibiotics, with amoxicillin accounting for 39.1 per cent of all prescriptions. Upper respiratory tract infections, many of them viral, were the leading reason for outpatient antibiotic use.

“Resistance to first-line antimicrobials increases the risk of morbidity and mortality. Unfortunately, the global rise in AMR has not been matched by the development of new antibiotics effective against resistant bacteria,” reads the paper in part. “As a result, healthcare costs are expected to rise, economic productivity will fall due to reduced workforce activity, and global life expectancy could drop by an estimated 1.8 years. This existential threat must be averted to avoid a post-antibiotic era in which even minor infections become fatal.”

Read together, the two studies provide a ground-level view of how AMR takes root long before a patient reaches a hospital or pharmacy. Poor-quality medicines remain widespread yet poorly understood, while health workers operate under heavy workloads, limited diagnostics, and outdated guidelines that make empirical treatment with antibiotics the default option.

These realities echo the warning delivered by Assoc. Prof. David Musoke, during his keynote address at the 10th National AMR Conference in Kampala on November 19, 2025. Speaking at the event organised by the National One Health Platform, institutionalised in 2016 under the Ministry of Health to coordinate AMR efforts, and held to mark World AMR Awareness Week 2025 under the theme Act Now: Protect Our Present, Secure Our Future, he cautioned that Uganda’s fight against AMR will falter unless communities are placed at the centre of national action.

“One in six bacterial infections globally, and one in five in Africa, are now resistant to available antibiotics,” Dr. Musoke said, citing the latest Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2025. “If Uganda is to make real progress, communities must be treated not as recipients of information but as genuine partners in the fight against AMR.”

What Must Change: Recommendations from the Researchers

To strengthen antimicrobial stewardship, the study on antibiotic prescribing recommends scaling up diagnostic capacity in public facilities so that treatment decisions are based on laboratory evidence rather than broad empirical prescribing, a medical term that means treatment initiated based on a clinician’s “educated guess” and clinical experience, in the absence of a definitive diagnosis or complete information about the specific cause of a disorder. Expanding functional microbiology services, the study says, would reduce reliance on broad-spectrum antibiotics, which accelerates resistance.

The authors also call for strict enforcement of national treatment guidelines, especially in surgical wards where antibiotics are routinely continued longer than clinically required. For them, reducing unnecessary prophylaxis, particularly in obstetric and gynaecological surgery, would go a long way in limiting misuse without compromising patient safety.

They further urge the Ministry of Health to eliminate non-recommended antibiotic combinations from routine use and ensure consistent stock management to prevent missed doses. This, in addition to strengthening Water, Sanitation, and Hygiene (WASH), and Infection-Prevention and Control (IPC) systems, combined with regular stewardship-focused training for prescribers, is highlighted as essential for improving prescribing standards. Finally, they recommend institutionalising routine point prevalence surveys in Uganda to track trends, guide facility-level action, and reinforce accountability for stewardship.

On the other hand, to address the widespread circulation of substandard and falsified medicines, the study team call for a nationwide effort to improve public literacy on how to recognise, verify, and report suspicious medical products. The authors also argue that current reporting pathways are largely invisible, leaving most community members unsure of how or where to lodge complaints. Strengthening the National Drug Authority’s visibility and making its reporting mechanisms simple and accessible, in that case, is identified as a critical first step.

They also highlight the need to engage frontline actors, and this includes Village Health Teams, Community Health Extension Workers, veterinary officers, and local leaders, as primary change agents. These trusted community structures, the authors assert, are well-positioned to translate regulatory messages into actionable information than mass-media campaigns alone.

Given the extensive use of suspected counterfeit veterinary medicines, the authors call for strengthened One Health education and a fully integrated communication approach linking human, animal, and plant health risks. They recommend sustained messaging through radio and other local media, supported by community-driven monitoring systems able to empower consumers to act as partners in protecting the medicine supply chain.

View on MakSPH